阿斯利康:公司与苏州宜联生物医药有限公司(“宜联生物”)正式签署临床研究合作协议。双方将基于在临床前研究中展现出的联用协同效应,共同探索阿斯利康免疫检查点抑制剂度伐利尤单抗联合宜联生物靶向B7H3的抗体偶联药物YL201治疗多种实体瘤的潜力。双方将共同启动一项多中心、开放性、I/Ib期研究,旨在评估两款药物联合治疗在实体肿瘤患者中的安全性、有效性和药代动力学。百济神州:公司首席执行官欧雷强在1月...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.